{"id":"placebo-matching-ubrogepant","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of calcitonin gene-related peptide (CGRP) at its receptor, which is involved in the transmission of pain signals in the brain. This leads to a reduction in the frequency and severity of migraine attacks.","oneSentence":"Ubrogepant is a calcitonin gene-related peptide receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:01.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute treatment of migraine attacks with or without aura"},{"name":"Prevention of migraine attacks"}]},"trialDetails":[{"nctId":"NCT05125302","phase":"PHASE3","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"Migraine","enrollment":1059},{"nctId":"NCT02873221","phase":"PHASE3","title":"An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-09-13","conditions":"Migraine, With or Without Aura","enrollment":1254},{"nctId":"NCT02867709","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-08-26","conditions":"Migraine, With or Without Aura","enrollment":1686},{"nctId":"NCT01613248","phase":"PHASE2","title":"A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-07-01","conditions":"Migraine","enrollment":834},{"nctId":"NCT02828020","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-22","conditions":"Migraine, With or Without Aura","enrollment":1672},{"nctId":"NCT01657370","phase":"PHASE2","title":"A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-08","conditions":"Migraine","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo-matching Ubrogepant","genericName":"Placebo-matching Ubrogepant","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ubrogepant is a calcitonin gene-related peptide receptor antagonist. Used for Acute treatment of migraine attacks with or without aura, Prevention of migraine attacks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}